We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.26%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.36B
AUM Growth
+$269M
Cap. Flow
-$71.3M
Cap. Flow %
-2.12%
Top 10 Hldgs %
68.61%
Holding
29
New
1
Increased
9
Reduced
13
Closed
2

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$43.6M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$33.6M
3
CEMP
Cempra, Inc.
CEMP
+$13.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.53M
5
TSRO
TESARO, Inc.
TSRO
+$7.07M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$89.4M
2
INCY icon
Incyte
INCY
+$21.5M
3
CELG
Celgene Corp
CELG
+$19.1M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$16.8M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 82.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$410M 12.21%
3,554,298
-160,000
-4% -$19.1M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.4B
$365M 10.87%
5,729,426
-247,100
-4% -$16.8M
INCY icon
3
Incyte
INCY
$24.4B
$348M 10.35%
3,791,867
-260,000
-6% -$21.5M
GILD icon
4
Gilead Sciences
GILD
$165B
$281M 8.38%
2,865,596
-80,000
-3% -$8.12M
AGIO icon
5
Agios Pharmaceuticals
AGIO
$1.93B
$174M 5.2%
1,849,921
-15,000
-0.8% -$1.68M
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
$165M 4.9%
2,549,412
-220,000
-8% -$12.6M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$126B
$157M 4.69%
1,334,445
-20,000
-1% -$2.4M
RDUS
8
DELISTED
Radius Health, Inc.
RDUS
$153M 4.56%
3,722,140
+970,000
+35% +$43.6M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.6B
$127M 3.79%
3,201,552
+115,000
+4% +$4.11M
PBYI icon
10
Puma Biotechnology
PBYI
$454M
$123M 3.67%
521,991
– –
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$117M 3.47%
672,428
– –
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$105M 3.12%
635,272
-15,909
-2% -$2.01M
GEVA
13
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$100M 2.98%
1,025,476
-105,000
-9% -$11.1M
HALO icon
14
Halozyme
HALO
$12.2B
$91.7M 2.73%
6,423,370
-402,162
-6% -$5.8M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$80.8B
$89.4M 2.66%
198,000
– –
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.3B
$87.2M 2.6%
835,499
+84,211
+11% +$8.53M
PTCT icon
17
PTC Therapeutics
PTCT
$6.12B
$71.7M 2.14%
1,177,912
-50,000
-4% -$3.05M
NVAX icon
18
Novavax
NVAX
$1.31B
$69.9M 2.08%
422,500
+27,500
+7% +$4.47M
TTPH
19
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$54.1M 1.61%
73,856
+8,750
+13% +$6.57M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$49.1M 1.46%
854,582
+150,000
+21% +$7.07M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$45.9M 1.37%
618,188
– –
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$43.7M 1.3%
+155,000
New +$33.6M
CEMP
23
DELISTED
Cempra, Inc.
CEMP
$42M 1.25%
1,223,000
+448,000
+58% +$13.5M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$36.6M 1.09%
2,620,737
+300,000
+13% +$4.59M
IMGN
25
DELISTED
Immunogen Inc
IMGN
$25.4M 0.76%
2,840,816
-400,000
-12% -$2.9M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2015 Portfolio in Review

As of Q1 2015, BB Biotech held 29 positions worth $3.36B, up 8.7% from $3.09B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

BB Biotech's Q1 2015 filing shows 1 new, 9 increased, 13 reduced and 2 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 155,000 shares worth $43.7M. The largest sale was PHARMACYCLICS INC, an estimated $89.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier.

  • BB Biotech's largest Q1 2015 buy was Intercept Pharmaceuticals, Inc.: 155,000 shares worth $43.7M.
  • BB Biotech added most to Radius Health, Inc. in Q1 2015, an estimated $43.6M increase.
  • BB Biotech's biggest Q1 2015 reduction was Incyte, cutting an estimated $21.5M.
  • BB Biotech fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $89.4M.
  • BB Biotech's ten largest holdings make up 69% of its $3.36B portfolio in Q1 2015.
  • BB Biotech opened 1 new position and closed 2 in Q1 2015.
  • BB Biotech's portfolio value rose 8.7% quarter-over-quarter to $3.36B.

Based on BB Biotech's 13F filing for Q1 2015, filed 14 May 2015.